Neil Kumar - Dec 3, 2021 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
CEO and President, Director
Signature
Yi Ching Yau, Attorney-in-Fact
Stock symbol
BBIO
Transactions as of
Dec 3, 2021
Transactions value $
$0
Form type
4
Date filed
12/7/2021, 05:14 PM
Previous filing
Nov 18, 2021
Next filing
Feb 18, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Stock Option (right to buy) Award $0 +786K $0.00 786K Dec 3, 2021 Common Stock 786K $38.62 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests and becomes exercisable as to 25% of the underlying shares on December 3, 2022 and thereafter in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.